| |MARCH 20268ZYDUS PARTNERS WITH LUPIN TO LAUNCH ITS WEIGHT LOSS INJECTION IN INDIAZydus has partnered with Lupin to launch its weight loss injection in India, marking a major step in expanding access to semaglutide in India for both diabetes and obesity treatment.The agreement allows Lupin to co-market Zydus' semaglutide injection, helping the drug reach patients faster across the country.The Zydus weight loss injection is based on semaglutide, a widely used molecule for managing type 2 diabetes and aiding weight loss. With patents nearing expiry, Indian pharmaceutical companies are moving quickly to introduce more affordable versions. This partnership gives Lupin semi-exclusive rights to distribute the drug, strengthening its presence in the fast-growing obesity treatment market in India.The injection will be offered through a reusable pen device, designed to improve convenience and long-term use. The companies aim to make the therapy more accessible compared to imported brands, which are often expensive for Indian patients. Rising cases of obesity and diabetes have created strong demand for effective treatments like semaglutide.Industry experts see this move as the beginning of increased competition in the semaglutide injection market in India, which could drive down prices and improve availability. Zydus brings manufacturing strength, while Lupin adds a wide distribution network, making the collaboration strategically significant.The launch is expected soon, positioning both companies to tap into a rapidly expanding segment. As more players enter the space, patients may benefit from better pricing and wider access to advanced therapies. POTOP STORIESASTRAZENECA INDIA RECEIVED REGULATORY APPROVAL FOR DURVALUMABAstraZeneca Pharma India has received regulatory approval for Durvalumab for liver cancer treatment in India, marking a significant step in expanding cancer care options.The approval allows the company to introduce this immunotherapy drug for patients with unresectable hepatocellular carcinoma, a common form of liver cancer where surgery is not possible.The Durvalumab for liver cancer treatment in India approval specifically applies to adult patients who have not received prior systemic therapy. This makes the drug a first-line treatment option, giving doctors an additional tool in cases where early intervention can make a meaningful difference.Durvalumab, globally known as Imfinzi, is an immunotherapy drug that works by helping the immune system detect and fight cancer cells more effectively. It has already been approved for multiple cancers worldwide, including lung and bladder cancer, and its expansion into liver cancer treatment highlights growing confidence in immunotherapy-based approaches.For India, where liver cancer is often diagnosed at advanced stages, this approval addresses a critical gap. Many patients are not eligible for surgery, making systemic therapies the only viable path. With this development, AstraZeneca India liver cancer treatment portfolio becomes stronger, offering new hope for patients with limited options.The move also reflects AstraZeneca's continued focus on oncology in India, particularly in bringing advanced cancer therapies to the market. As demand rises for innovative treatments, approvals like this could reshape how liver cancer is managed in the country. PO
< Page 7 | Page 9 >